102 - OBESITY AND CVD – CURRENT IMPERATIVES FOR IMPROVING PATIENT OUTCOMES

Thursday, October 24, 2024

12:30 PM – 1:30 PM PT

Room: 109-110

Join us for an accredited symposium on obesity and cardiovascular disease (CVD), presented at the Canadian Cardiovascular Congress 2024 and designed for cardiologists, endocrinologists, family physicians, and allied health professionals. This 1-hour live symposium aims to provide participants with a comprehensive understanding of the impact of obesity on cardiovascular health, the role of lifestyle and pharmacological interventions in CVD prevention, and strategies for implementing comprehensive obesity and CVD management in clinical practice. Participants will learn practical tips for integrating evidence-based interventions into patient care through interactive case studies and discussions around current guidelines

Learning Objectives:

At the end of this session participants will be able to:

Describe the effect of obesity on cardiovascular health and its role as a modifiable risk factor for CVD;
Discuss the role of cardiologists in primary and secondary prevention of CVD for people with obesity; and
Integrate evidence-based pharmacological and lifestyle interventions for obesity management into comprehensive care plans for CVD prevention; and
identify strategies to improve multidisciplinary collaboration and equitable access to obesity management in cardiovascular care

Disclosure(s):

Elizabeth A. Swiggum, MD, FRCPC, FCCS: BI Lilly Alliance: Advisory Board (Ongoing), Consulting Fees/Honoraria (Ongoing); Boehriger Ingelheim: Advisory Board (Ongoing), Consulting Fees/Honoraria (Ongoing), Multicentre tiral (Ongoing); Canadian Medical and Surgical Knowledge Translation Research Group: Speaker (Ongoing); Novartis: Advisory Board (Ongoing), Consulting Fees/Honoraria (Ongoing); NovoNordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Advisory Board (Ongoing), Amyloid clinic QI project funding (Ongoing)

Grace L. Chua, MD, FRCP, FESC: Abbott: Consultant/Advisory Board (Ongoing); Eli-Lilly: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); GSK: Consultant/Advisory Board (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Speaker/Honoraria (Ongoing)

Nathaniel Moulson, MD, MHA, FRCPC: Amgen: Honoraria received (Ongoing); HLS Therapeutics: Honoraria received (Ongoing); Novartis: Honoraria received (Ongoing); Novo Nordisk: Advisory Board (Ongoing); Sanofi: Honoraria received (Ongoing)

A. Shekhar Shekhar PANDEY, MD, FRCPC, ABIM, CBNC: No financial relationships to disclose

Co-Chair(s)

JM

John Mancini, MD, FRCPC, FACP, FACC

Professor of Medicine, University of British Columbia
University of British Columbia
University of British Columbia
Elizabeth A. Swiggum, MD, FRCPC, FCCS (she/her/hers)

Medical Director Heart Function Clinic, Cardiac Rehabilitation Royal Jubilee Hospital
CHFS
University of British Columbia

Presenter(s)

Grace L. Chua, MD,FRCPC,FACC

Staff Cardiologist
Mackenzie Health
NM

Nathaniel Moulson, MD, MHA, FRCPC

Clinical Assistant Professor
University of British Columbia
University of British Columbia
A. Shekhar Shekhar PANDEY, MD, FRCPC, ABIM, CBNC (he/him/his)

Cardiologist
Yes
McMaster University
Paul Poirier, MD, PhD, FRCPC, FACC, FAHA, FCCS

Cardiologist
Université Laval
Universite Laval